Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02497547
Other study ID # OXYPEP201
Secondary ID
Status Completed
Phase Phase 2
First received July 6, 2015
Last updated October 20, 2015
Start date October 2014
Est. completion date July 2015

Study information

Verified date October 2015
Source PeP-Tonic Medical AB
Contact n/a
Is FDA regulated No
Health authority Sweden: Medical Products AgencySweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

Up to 50% of postmenopausal women frequently suffer from atrophic vaginitis or vaginal atrophy with symptoms including vaginal dryness, irritation, burning, itching or discomfort. Vaginal atrophy is a consequence of the lining tissue of the vagina becoming thinner, drier, and less elastic due to lack of estrogen. In addition, vaginal atrophy is associated with an increased pH, which creates an environment more susceptible to infections.

Menopausal hormone therapy is a common treatment for vaginal atrophy. However, menopausal hormone therapy has been shown to coincide with an increased incidence of breast cancer, heart attack and stroke. Some women experience adverse reactions such as uterine bleeding, perineal pain, and breast pain with menopausal hormone therapy. Many women are also reluctant to initiate estrogen treatment, due to a general negative view of menopausal hormone therapy in the society. There are also many contraindicated conditions like undiagnosed vaginal bleeding, thromboembolic disease, breast cancer, other estrogen-sensitive cancers, or liver disease. Women suffering from vaginal atrophy and presenting with these conditions have extremely limited options for effective therapy.

Oxytocin is a peptide hormone, normally released into the circulation via the pituitary. Oxytocin has been shown in vitro to exert positive effects on the proliferation of human vaginal mucosal cells from postmenopausal women. Local application of oxytocin, in the form of a vaginal gel, Vagitocin, has been investigated in previous studies on postmenopausal women, as a new effective and safe option for the treatment of vaginal atrophy. Vagitocin appeared to reverse the manifestation of vaginal atrophy by stimulating vaginal mucosal growth, reducing symptoms of vaginal atrophy and increasing the patients' wellbeing and quality of life. Overall, treatment with Vagitocin was safe and well tolerated by the subjects in the studies.

In this study, the clinical efficacy of Vagitocin as a potential treatment for postmenopausal women suffering from moderate to severe symptoms of vaginal atrophy, vaginal irritation/itching and vaginal discomfort and/or pain associated with sexual activity will be explored. In addition, the dose relationship and lowest effective dose of Vagitocin will be investigated.


Recruitment information / eligibility

Status Completed
Enrollment 227
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria:

To participate in the study, a subject must:

1. Be a female subject between the ages of 40 and 65 years at the time of randomization, who is willing to participate in the study as indicated by signing the informed consent

2. Be a postmenopausal woman with at least 24 months of spontaneous amenorrhea or a woman, who has had surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks ago

3. Have = 5% superficial cells in vaginal smear cytology at screening

4. Have a vaginal pH > 5.0 at screening

5. Have a level of estradiol = 30 pg/mL and a level of Follicle Stimulating Hormone (FSH) > 40 milli International Units (mIU)/ml at screening

6. Have one moderate to severe vaginal atrophy symptom (vaginal irritation and itching, dyspareunia, vaginal dryness, dysuria or presence of vaginal bleeding associated with sexual activity) that has been identified by the subject as being the most bothersome to her

7. Have a Body Mass Index (BMI) =32 kg/m2

8. Be judged by the Principal Investigator or Sub-investigator as being in otherwise good health based on a pre-study medical evaluation performed within 35 days prior to the initial dose of study medication

9. Have endometrial thickness of < 4 mm as determined by vaginal ultrasonography, in women with an intact uterus

10. Be willing to abstain from sexual activity and the use of vaginal douching within 24 hours prior to vaginal pH measurements at screening and at Visits 2 and 3

Exclusion Criteria:

To participate in the study, a subject must not:

1. Be currently hospitalized

2. Have a history of ongoing cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, or musculoskeletal disease or disorder that is clinically significant in the opinion of the Principal Investigator or Sub-Investigator

3. Have had or have any known or suspected tumor disease that is clinically significant in the opinion of the Principal Investigator or Sub-Investigator

4. Have a history of endometrial hyperplasia or uterine/endometrial, breast or ovarian cancer

5. Have a history of undiagnosed vaginal bleeding

6. Have an ongoing urogenital infection at randomization visit

7. Any contraindication to oxytocin therapy and allergy to the use of oxytocin and any components of the investigational drugs

8. Have a history of drug and/or alcohol abuse within one year of start of study

9. Have used any prescription or Over The Counter (OTC) medications including phytoestrogens, herbal medicinal products or hormonal intra-uterine device with known estrogenic effects within 12 weeks prior to screening procedures

10. Have used any type of vaginal lubricants and moisturizers within 24 hours prior to screening procedures

11. Have used estrogen alone or estrogen/progestin for any of the time periods specified in the protocol

12. Have any reason, which in the opinion of the Principal Investigator or Sub-Investigator would prevent the subject from safely participating in the study or complying with protocol requirements

13. Have participated in another clinical trial within 90 days prior to screening, have received an investigational drug within the three months prior to the initial dose of study medication, or be likely to participate in a clinical trial or receive another investigational medication during the study

14. Have contraindication to any planned study procedure

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Oxytocin

Placebo


Locations

Country Name City State
Sweden Hoftekliniken Helsingborg
Sweden Qvinnolivet Specialistläkarna Kungsbacka Kungsbacka
Sweden Kvinnoforskningsenheten, Karolinska Universitetssjukhuset, Huddinge Stockholm
Sweden Kvinnokliniken, Norrlands Universitetssjukhus Umeå
Sweden Kvinnokliniken, Akademiska sjukhuset Uppsala

Sponsors (2)

Lead Sponsor Collaborator
PeP-Tonic Medical AB A+ Science AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to Week 12 in severity of vaginal atrophy symptom that has been self-identified by the subject as being the most bothersome to her in the vaginal atrophy questionnaire Vaginal atrophy symptoms: vaginal irritation and itching, dyspareunia, vaginal dryness, dysuria or presence of vaginal bleeding associated with sexual activity After 12 weeks of treatment No
Primary Change from baseline to Week 12 in % superficial cells (increase is positive) After 12 weeks of treatment No
Primary Change from baseline to Week 12 in Vaginal pH (decrease is positive) After 12 weeks of treatment No
Secondary Change from baseline to Week 4 in severity of the vaginal atrophy symptoms that has been self-identified by the subject as being the most bothersome to her in the vaginal atrophy questionnaire Vaginal atrophy symptoms: vaginal irritation and itching, dyspareunia, vaginal dryness, dysuria and the absence or presence of vaginal bleeding associated with sexual activity After 4 weeks of treatment No
Secondary Change from baseline to Week 4 in % superficial cells (increase is positive) After 4 weeks of treatment No
Secondary Change from baseline to Week 4 in vaginal pH (decrease is positive) After 4 weeks of treatment No
Secondary Change from baseline to week 4 and 12 of % parabasal cells (decrease is positive) After 4 and 12 weeks of treatment No
Secondary Change from baseline to week 4 and 12 of maturation value (increase is positive) After 4 and 12 weeks of treatment No
Secondary Change from baseline to Weeks 4 and 12 in severity of vaginal atrophy symptoms self-assessed by the subject in the vaginal atrophy questionnaire Vaginal atrophy symtoms: vulvar and vaginal irritation and itching, dyspareunia, vaginal dryness, dysuria and the absence or presence of vaginal bleeding associated with sexual activity After 4 and 12 weeks of treatment No
Secondary Change from baseline to Week 12 in Quality of Life evaluation parameters After 12 weeks of treatment No
See also
  Status Clinical Trial Phase
Completed NCT02781623 - Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture
Completed NCT02332343 - Sparing of the Fovea in Geographic Atrophy Progression N/A
Completed NCT00566982 - A Clinical Study to Evaluate the Safety of Ospemifene Phase 3
Completed NCT01586364 - Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus Phase 3
Active, not recruiting NCT05698316 - A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
Recruiting NCT05869812 - Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes Phase 2
Completed NCT02747641 - Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects N/A
Completed NCT02770365 - Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy Phase 3
Recruiting NCT02137824 - A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients N/A
Completed NCT01585558 - Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus Phase 3
Completed NCT02868749 - Histology and Ultrasound Pilot Study of HA Gels Adipose Tissue N/A
Recruiting NCT01911312 - Evaluation of Thermal-Aided Muscle Stimulation N/A
Completed NCT00729469 - Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity Phase 3
Completed NCT01553773 - Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment Phase 2
Recruiting NCT02745366 - Buccal Fat Pad Derived Stem Cells With Cortical Tenting in Posterior Mandible Reconstruction Phase 1
Completed NCT00744094 - Resistance Training in Elderly Phase 1/Phase 2
Completed NCT00807508 - Leucine Supplementation in Elderly Men Phase 1/Phase 2
Completed NCT00276094 - A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Phase 3
Terminated NCT00292916 - Effect of Whole Body Vibration on Bone and Fall Related Parameters Phase 3
Terminated NCT00267839 - Effect of Exercise on Risk-factors of Elderly Women Phase 3